Odyssey Therapeutics, Inc.
corporate_fare Company Profile
Odyssey Therapeutics, Inc. (NASDAQ:ODTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for ODTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for ODTX spans 8-K, 10-Q, SCHEDULE 13D, 424B4.
Recent high-impact activity:
- Odyssey Q3 2026: $387M Cash Through H2 2028, OD-002 IND Work Complete
- Odyssey Posts $53.1M Q3 Loss, $387M Cash Funds Runway Into H2 2028
- Odyssey's OD-001 Clears Phase 2a Primary Endpoint in Ulcerative Colitis
- Odyssey's OD-001 Hits Phase 2a Endpoint in Ulcerative Colitis, 20 mg BID Dose Selected
- Pipeline Update: OD-002 CTA Filing on Track for H2 2026, Detailed OD-001 Phase 2a Results
Short Interest & Short Volume
15.43 days to coverFINRA reported short interest of 3,347,791 shares in ODTX as of the October 30, 2026 settlement, a 2.0% increase from the prior period — about 15.4 days to cover at its recent average daily volume. On November 20, 2026, 71.2% of ODTX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.